BioCatalystWatch
AGIOWorkspace / AGIO / OverviewCompany library
AGIOS PHARMACEUTICALS, INC. logo

AGIOS PHARMACEUTICALS, INC.

AGIOS PHARMACEUTICALS, INC. (AGIO)

Website

Price
Market cap
Next catalystDec 12, 2026mitapivat (PYRUKYND) · Phase 3 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

AG-236

TMPRSS6

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

mitapivat (PYRUKYND)

pyruvate kinase (PK)

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

mitapivat (PYRUKYND)

pyruvate kinase (PK)

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

AG-181

PAH

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

AG-236

TMPRSS6

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AG-236

TMPRSS6

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

AG-181

PAH

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

AG-236

TMPRSS6

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

mitapivat (PYRUKYND)

pyruvate kinase (PK)

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

mitapivat (PYRUKYND)

pyruvate kinase (PK)

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

mitapivat (PYRUKYND)

pyruvate kinase (PK)

mitapivat (PYRUKYND)

pyruvate kinase (PK)

mitapivat (PYRUKYND)

pyruvate kinase (PK)

mitapivat (PYRUKYND)

pyruvate kinase (PK)

ivosidenib (TIBSOVO)

Mutant IDH1

PreINDP1P2P3FilingApproved

Partner / License out

ivosidenib (TIBSOVO)

Mutant IDH1

PreINDP1P2P3FilingApproved

Approved / commercial

mitapivat (PYRUKYND)

pyruvate kinase (PK)

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AGIO PR & News

PR & News

AGIO SEC archive